Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ARGX
ARGX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ARGX News
argenx Hosts Webinar on Advancing FcRn Leadership in Autoimmune Myositis
3d ago
Newsfilter
argenx Management to Attend Investor Conferences in June
4d ago
Newsfilter
MindWalk Reports Significant Progress in Drug Development
May 18 2026
Newsfilter
argenx SE Receives FDA Approval for VYVGART Label Expansion
May 11 2026
NASDAQ.COM
FDA Approves Label Expansion for Vyvgart in Myasthenia Gravis
May 09 2026
seekingalpha
FDA Approves VYVGART for All Adult gMG Patients
May 08 2026
Newsfilter
argenx SE Q1 Earnings Beat Expectations
May 07 2026
seekingalpha
argenx CEO to Present at BofA Healthcare Conference
May 06 2026
Newsfilter
argenx SE to Announce Q1 Earnings on May 7
May 06 2026
seekingalpha
argenx to Host Q1 2026 Financial Results Conference Call on May 7
Apr 30 2026
Newsfilter
VYVGART Shows Significant Symptom Improvement in Ocular Myasthenia Gravis Treatment
Apr 18 2026
Newsfilter
Analysis of IBB ETF Trading Dynamics
Mar 11 2026
NASDAQ.COM
Dianthus Therapeutics Early Decision Boosts Stock Surge
Mar 09 2026
stocktwits
VYVGART Shows Promise as Targeted Treatment for Ocular Myasthenia Gravis
Mar 06 2026
Newsfilter
argenx SE Reports Positive Phase 3 Results for VYVGART in Ocular Myasthenia Gravis
Mar 06 2026
Yahoo Finance
Significant Milestones in Biotech Sector This Week
Feb 27 2026
NASDAQ.COM
Show More News
